Trial
NCT04047797
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Mantle Cell Lymphoma
Intervention
Ixazomib
Why stopped
Administratively Complete 75%\<Participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-20